Search

Chlorphenesin

Imetelstat

[erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A263973] It is used to treat anemia in patients with myelodysplastic syndromes (MDS), a group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenia, abnormal marrow

Ritonavir

Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimen...

Osilodrostat

[L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013 … Osilodrostat is manufactured by Novartis under the brand name Isturisa.

Modafinil

Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. … The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular

Empagliflozin

[remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. … [L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for

Benzydamine

benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but

Prochlorperazine

[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. … [label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.

Vancomycin

29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by

Mebendazole

A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]